Combinatorial Targeted Therapy in Thyroid Cancer.
10.3342/kjorl-hns.2010.53.4.203
- Author:
Yoon Woo KOH
1
Author Information
1. Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea. ywkohent@yuhs.ac
- Publication Type:Review
- Keywords:
Targeted therapy;
Protein kinase;
Feedback loops;
Thyroid cancer
- MeSH:
Antibodies, Monoclonal;
Humans;
Phosphotransferases;
Protein Kinases;
Thyroid Gland;
Thyroid Neoplasms
- From:Korean Journal of Otolaryngology - Head and Neck Surgery
2010;53(4):203-208
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The elucidation of the signal-transduction pathways that drive neoplastic transformation has led to novel rationally designed cancer therapeutics (targeted therapy). Several compounds directed against different molecular pathways are being tested in patients with advanced thyroid carcinoma. Anticancer drugs that target protein kinases include small molecule inhibitors and monoclonal antibodies. Feedback loops and cross talk between signaling pathways impact significantly on the efficacy of cancer therapeutics, and resistance to targeted agents is a major barrier to effective treatments. Increasingly, therapies are being designed to target multiple kinase pathways. This can be achieved using a single agent that inhibits multiple signaling pathways or a combination of highly selective agents. In this review we discuss the principles of specifically targeting multiple kinase pathways with particular reference to targeted therapy for thyroid cancer.
